Matt Korda, the associate director of the Nuclear Information Project at the Federation of American Scientists, assisted USA ...
Eli Lilly (LLY) stock is in focus as Nimbus Therapeutics expands its research deal to develop an oral obesity drug in a deal ...
Renaissance IPO ETF (IPO) is rated a buy, anticipating a surge in major IPOs through 2026 to fuel renewed investor interest.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback